SMS Pharmaceuticals gets non-exclusive licence to manufacture, supply of nirmatrelvir

21 Mar 2022 Evaluate

SMS Pharmaceuticals has received a non-exclusive licence to manufacture and supply of nirmatrelvir through the Medicine Patent Pool to manufacture nirmatrelvir, an oral anti-viral COVID-19 medicine developed by Pfizer to increase broad access of treatment in 95 low and middle income countries.

SMS Pharmaceuticals is a global player in API and intermediates manufacturing having a strong research and manufacturing team supported by state?of?the?art facilities.

SMS Pharmaceuticals Share Price

420.20 38.00 (9.94%)
10-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1813.00
Dr. Reddys Lab 1313.90
Cipla 1333.10
Zydus Lifesciences 922.90
Lupin 2340.75
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×